NeuroSense Therapeutics (NASDAQ:NRSN – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.11) earnings per share for the quarter, Zacks reports.
NeuroSense Therapeutics Price Performance
Shares of NASDAQ NRSN opened at $1.28 on Friday. The firm has a fifty day moving average price of $1.12 and a 200-day moving average price of $1.03. NeuroSense Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.33. The stock has a market cap of $17.49 million, a PE ratio of -1.51 and a beta of 1.38.
Analyst Upgrades and Downgrades
Separately, Maxim Group reissued a “hold” rating on shares of NeuroSense Therapeutics in a report on Monday.
NeuroSense Therapeutics Company Profile
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.
See Also
- Five stocks we like better than NeuroSense Therapeutics
- How to Start Investing in Real Estate
- Palantir’s Momentum Persists Despite Market Worries
- What is the Euro STOXX 50 Index?
- Ad Sales to Top $1 Trillion: 3 Stocks to Take Advantage
- Stock Sentiment Analysis: How it Works
- Micron Stock Under $100: Seize the AI-Driven Upside
Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
